MSB does not even have a revenue generating product at all. You seem to always forget that.
I am not trying to discredit you. You have posted incorrect information, which I am certainly entitled to correct. SRX treatment as end of line therapy is growing at double digits every quarter. Last I have seen, the market penetration is still single digits of addressable market, and total addressable market is growing. This alone is more than enough. First line treatment would have been icing on the cake, but not required. The SP fell massively, yet you have somehow forgotten the before the fall, the SP has risen by many magnitudes. Holders today are seeing at least 500% gains despite the fall.
MSB does not even have a revenue generating product at all. You...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |